Expanding Manufacturing Capabilities Pharmaron has invested heavily in expanding its manufacturing infrastructure, including a $190 million investment in mRNA and gene therapy production facilities across Europe, indicating a strong capacity for scalable biologics and advanced therapies. This positions the company as a strategic partner for clients seeking large-scale manufacturing solutions in gene and cell therapies.

Strategic Industry Partnerships Recent collaborations with industry leaders such as Eli Lilly and CN Bio demonstrate Pharmaron's active involvement in cutting-edge drug discovery and development technologies, creating opportunities to offer tailored R&D and CMC services aligned with innovative therapeutic modalities like biologics and cell and gene therapies.

Diversified Service Portfolio With comprehensive services spanning synthetic chemistry, biologics, radiochemistry, toxicology, and clinical development, Pharmaron can address a wide range of client needs for drug discovery and development, making it an ideal partner for both early-stage R&D and late-stage manufacturing projects.

Global R&D Platform Pharmaron’s global presence and ongoing development of OOC (Organ-on-a-Chip) technologies offer opportunities to collaborate with companies aiming to accelerate drug testing and precision medicine applications, particularly in biologics and personalized therapies.

Financial Strength & Stability With a robust revenue range of up to $10 billion and significant funding support, Pharmaron demonstrates financial stability and growth potential, enabling long-term partnerships in high-value areas such as gene therapy, biologics manufacturing, and innovative drug discovery services.